TransCode Therapeutics shareholders reject reverse stock split proposal at annual meeting

Transcode Therapeutics, Inc.

Reverse stock split proposal failed: 1,018,164 for, 1,277,915 against, 96,498 abstain.
All four director nominees elected: Philippe Calais, Thomas Fitzgerald, Erik Manting, Magda Marquet.
Stock plan amendment approved: 526,212 for, 205,773 against, 4,853 abstain.
Auditor WithumSmith+Brown ratified: 2,193,452 for, 159,569 against, 39,556 abstain.
Adjournment proposal passed but no adjournment motion made.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.